Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report

Table 3 T_max and T_1/2 (mean (SD)) of aripiprazole after administration of long acting injectable aripiprazole (Abilify Maintena®) and aripiprazole lauroxil (Aristada®)

	After single gluteal injection of aripiprazole 400 mg equivalents		After 4th gluteal injection of aripiprazole 300 mg equivalents^a
	Aripiprazole LAI	Aripiprazole lauroxil	Aripiprazole LAI	Aripiprazole lauroxil
T_max (day)	22 (4–22)^b	44.0 (11.7)	6.5 (0.5–21.2)^b	21.1
T_1/2 (day)	10.5 (3.9)	18.0 (4.8)	29.9 (8.0)	29 (6)

^aPharmacokinetic parameters at steady-state. Data for the 400 mg equivalents is not available for aripiprazole lauroxil. For the purpose of comparison between two agents, data for the 300 mg equivalents is included
^bReported as median (range)

ISSN: 1471-244X